Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03776812 · ClinicalTrials.gov registry record · Phase 2
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase 2 study, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 178
- Enrollment target
NCT03776812 is a Phase 2 study that has completed, run by Corcept Therapeutics. The registered enrollment target is 178 participants.
The verdict
NCT03776812, a Phase 2 study, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 178 participants
- Enrollment target
Study Summary
This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone.
Interventions
- DRUG Nab-paclitaxel
- DRUG Relacorilant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2019-04-05 |
| Est. Completion | 2023-07-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03776812
The ClinicalTrials.gov registry entry for NCT03776812 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nab-paclitaxel is the first listed.
NCT03776812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03776812 about?
NCT03776812 is a clinical study titled "Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel c...
What is the current status of trial NCT03776812?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 178 participants. The study started on 2019-04-05. Estimated completion is 2023-07-12.
What interventions are being tested in trial NCT03776812?
The interventions under investigation include: Nab-paclitaxel (DRUG), Relacorilant (DRUG).
Who is sponsoring clinical trial NCT03776812?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.